Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Eliquis

Bristol-Myers Squibb (BMS) building

Yale Cancer Center joins BMS’ II-ON

Becomes the 16th institute to join the network

- PMLiVE

Merck/Pfizer’s cancer immunotherapy latecomer hits a snag

Bavencio fails a key lung cancer trial

Bristol-Myers Squibb (BMS) building

BMS pens massive $3.6bn deal for Nektar cancer immunotherapy

Nektar’s NKTR-214 to be paired with Opdivo and Yervoy in a host of tumour types

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo plus Yervoy aces phase III trial

The cancer drug combo met one of its primary endpoints in NSCLC patients

Bristol-Myers Squibb (BMS) building

BMS’ Yervoy picks up another indication in Europe

The EC licenses the immuno-oncology treatment for children with skin cancer

- PMLiVE

Merck closes in on adjuvant melanoma indication for Keytruda

Its immunotherapy could catch up with BMS’ Opdivo if approved

Bristol-Myers Squibb (BMS) building

BMS adds another Ono drug to its immuno-oncology portfolio

Pharma giant hopes its new candidate can follow in the footsteps of Opdivo

Bristol Myers Squibb logo

Bad news for Innate Pharma as BMS-backed drug stumbles

Lirilumab combination fails to show additional benefit in SCCHN patients

Bristol-Myers Squibb (BMS) building

BMS adds another EU indication to Opdivo’s growing list

Wins European licence to treat high-risk advanced melanoma

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo/Yervoy combination demonstrates OS benefit

Better kidney cancer symptom control reported versus sunitinib was also reported

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo defies naysayers with healthy growth

Third quarter sales of the PD1 inhibitor saw a 38% rise

- PMLiVE

BMS appoints Saurabh Saha as senior VP, global head of translational medicine

He joins the R&D team from Atlas Venture

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links